Immunosuppressive Drug Therapy in Lupus Nephritis

American Journal of Kidney Diseases

Volumn 21, Issue 3, 1993, Pages 239-250

  Donadio, James V ^a,b   Glassock, Richard J ^a,b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Immunosuppressive therapy; lupus nephritis

Indexed keywords

ACROLEIN; ALKYLATING AGENT; AZATHIOPRINE; CHLORAMBUCIL; CHLORMETHINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; HEPARIN; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; MESNA; METHYLPREDNISOLONE; PREDNISONE; PROCARBAZINE;

ALOPECIA; AMENORRHEA; BLADDER CANCER; CARCINOGENESIS; CYTOPENIA; DISEASE COURSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; HEART FAILURE; HEMORRHAGIC CYSTITIS; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LUNG FIBROSIS; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE FUNCTION; MACROCYTIC ANEMIA; METABOLIC DISORDER; MYELOID LEUKEMIA; NAUSEA; NONHODGKIN LYMPHOMA; OLIGOSPERMIA; OPPORTUNISTIC INFECTION; ORAL DRUG ADMINISTRATION; PANCREATITIS; REVIEW; SQUAMOUS CELL CARCINOMA; SURVIVAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TERATOGENICITY; WATER INTOXICATION;

EID: 0027471386     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(12)80741-4     Document Type: Article

References (80)

1. Studies on condensed pyrimidine systems
2. A summary of investigations with 6-[(1-methyl-4-nitro-5-imidazolyl)thio]purine (B.W
3. Chemical action and pharmacology of methotrexate, azathioprine and cyclophosphamide in man
4. Azathioprine
5. Immunosuppressive agents
6. Time-dependence and selectivity of immunosuppressive agents
7. The effects of azathioprine and 6 MP on immunity
8. Is azathioprine a better immunosuppressive than 6-mercaptopurineqqqq
9. Biochemistry and pharmacology of purine analogues
10. Immunodepressant activity and 6-mercaptopurine levels after administration of 6-mercaptopurine and azathioprine
11. Immunosuppressive agents
12. The alkylating agents
13. Clinical pharmacokinetics of cyclophosphamide
14. The effect of mustard gas (dichlorethylsulphid) on antibody formation
15. Immunosuppressive drugs
16. Selective depletion of lymphoid tissue by cyclophosphamide
17. Studies on the mechanism of action of methotrexate and cyclophosphamide on contact sensitivity in the guinea pig
18. Enhancement of dinitrochlorbenzene (DNCB) contact sensitization by cyclophosphamide in the guinea pig
19. Activation of human B lymphocytes
20. Sensitivity of murine B- and Tlymphocytes to oxazaphosphorine and non-oxazaphosphorine nitrogen mustards
21. Oxazaphosphorines
22. Oxazaphosphorines as biological response modifiers-Experimental and clinical perspectives
23. The effect of treatment with prednisone and nitrogen mustard on the renal lesions and life span of patients with lupus glomerulonephritis
24. Controlled trial of cyclophosphamide, azathioprine and chlorambucil in lupus nephritis
25. The incidence of malignancies in transplant recipients
26. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs
27. Lupus nephritis
28. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment
29. Late effects of immunosuppressive anticancer drugs
30. Treatment of diffuse proliferative nephritis with prednisone and combined prednisone and cyclophosphamide
31. Azathioprine and acute restrictive lung disease
32. Cyclophosphamide therapy and interstitial pulmonary fibrosis
33. The use of cultured rat embryos to evaluate the teratogenic activity of serum: Cadmium and cyclophosphamide
34. Teratogenicity of structural truncates of cyclophosphamide in mice
35. Cytotoxic drugs in pregnancy: Review of reported cases
36. Renal agenesis after first trimester exposure to chlorambucil
37. Fetal effects during cyclophosphamide and irradiation therapy
38. Teratogenic effects of combination chemotherapy
39. Teratogenic effects of first-trimester cyclophosphamide therapy
40. Acute leukemia following cyclophosphamide therapy for Sj6gren's syndrome
41. Treatment of lupus nephritis with prednisone and combined prednisone and azathioprine
42. Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus: Report of a prospective controlled trial in 24 patients
43. Cyclophosphamide and urinary bladder toxicity
44. Bladder complications in patients receiving cyclophosphamide for systemic lupus erythematosus or rheumatoid arthritis
45. Cyclophosphamide-induced bladder toxicity in Wegener's granulomatosis
46. Wegener granulomatosis: An analysis of 158 patients
47. Intermittent intravenous cyclophosphamide therapy for lupus nephritis
48. Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus
49. The histological effects of nitrogen mustards on human tumors and tissues
50. Alkylating agents and human spermatogenesis
51. Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer
52. Gonadal function in boys with steroid-responsive nephrotic syndrome treated with cyclophosphamide for short periods
53. Diffuse proliferative lupus nephritis: Identification of specific pathologic features affecting renal outcome
54. Predictive value of renal pathology in diffuse proliferative lupus glomerulonephritis
55. The value of the renal biopsy in lupus nephritis
56. How important is renal biopsy in managing patients with renal diseaseqqqq. The case against its utility: Lupus nephritis
57. The treatment of lupus nephritis
58. The long-term outcome of glomerular diseases
59. Azathioprine and prednisone in the treatment of adults with lupus nephritis: Clinical, histological, and immunological changes with therapy
60. Effect of azathioprine on renal histology and function in lupus nephritis
61. The effect of azathioprine on lupus glomerulonephritis
62. Treatment of lupus nephritis with cyclophosphamide
63. Cyclophosphamide in systemic lupus erythematosus
64. Cyclophosphamide in treatment of systemic lupus erythematosus: 7 years experience
65. Azathioprine in the treatment of systemic lupus erythematosus: A controlled study
66. Comparison of azathioprine, prednisone, and heparin alone or combined in treating lupus nephritis
67. Long-term prognosis of diffuse lupus nephritis
68. Further observations on the treatment of lupus nephritis with prednisone and combined prednisone and azathioprine
69. Cyclophosphamide or azathioprine in lupus glomerulonephritis
70. Alternative modes of cyclophosphamide and azathioprine therapy in lupus nephritis
71. Controlled studies of oral immunosuppressive drugs in lupus nephritis: A long-term followup
72. Effect of treatment on the evolution of renal abnormalities in lupus nephritis
73. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only
74. Design and analysis of randomized clinical trials requiring prolonged observation of each patient
75. Cytotoxic drug treatment of lupus nephritis
76. The clinical course of lupus nephritis: Relationship to the renal histologic findings
77. The natural history of the renal manifestations of systemic lupus erythematosus
78. The clinical course of the proliferative and membranous forms of lupus nephritis
79. Cyclophosphamide: To pulse or not to pulseqqqq